Advertisement
Advertisement
U.S. Markets open in 3 hrs 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
23.68-0.35 (-1.46%)
At close: 04:00PM EDT
23.70 +0.02 (+0.08%)
After hours: 07:25PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close24.03
Open24.23
Bid0.00 x 1800
Ask0.00 x 1100
Day's Range23.14 - 24.64
52 Week Range19.34 - 96.88
Volume1,605,983
Avg. Volume933,174
Market Cap1.25B
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-0.35
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est60.29
  • Business Wire

    CareDx The Transplant Company Releases Inaugural Environmental, Social and Governance Report

    SOUTH SAN FRANCISCO, Calif., June 21, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the release of its first environmental, social and governance (ESG) report.

  • Business Wire

    CareDx To Participate in Upcoming Jefferies Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., June 02, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Jefferies Healthcare Conference on June 9th, 2022.

  • Business Wire

    CareDx Leads Transplant Innovation with AiKidney, an AI Clinical Decision Support Tool for Predicting Allograft Rejection Risk

    SOUTH SAN FRANCISCO, Calif., June 02, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it plans to expand its growing multimodality portfolio with AiKidney™, a new allograft risk assessment clinical decision support tool, in development, that includes AlloSure® and other transplant metrics.

Advertisement
Advertisement